Akebia Therapeutics
Praliciguat
Focal Segmental Glomerulosclerosis
Countdown
358days
Phase 2 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 2 trial results for Praliciguat in Focal Segmental Glomerulosclerosis are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT07268638: Phase 2 trial, sponsor Akebia Therapeutics, drug Praliciguat. Primary completion date 2027-06 (estimated).”